Rosetta Regains US Rights to miRNA Cancer Diagnostics, Addresses QC Issue at Diagnostics Lab

The company also reported its third-quarter financial results, posting a rise in losses amid higher expenses.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.